This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

W. L. Whittington; S. J. Kraus, MD; Francis Lee, MS; Andre J. Nahmias, MD
Centers for Disease Control Emory University School of Medicine Atlanta

JAMA. 1986;255(13):1702-1703.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.—

The prevalence of antibodies to human T-cell lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) in those groups with the highest incidence of acquired immunodeficiency syndrome has been investigated vigorously. Reports of the heterosexual transmission of HTLVIII/LAV from both intravenous drug abusers and hemophiliacs to their sexual partners^1,2 have given credence to the theory that the virus is being introduced into populations without established risk factors in North America and Europe. The prevalence of antibody to HTLV-III/LAV in sexually active heterosexuals is unknown but is thought to be low.

As an adjunct to a study of the prevalence of antibodies to herpes simplex viruses in serum samples obtained from heterosexuals attending a sexually transmitted disease clinic during 1985, we determined the prevalence of antibodies to HTLV-III/LAV. Serum samples were screened by enzyme immunoassay, and those found positive were "confirmed" by Western blot technique.³ Two (1.1%) of 185 . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?